ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	2.44T
Revenue (ttm)	318.32B
Net Income (ttm)	36.89B
Shares Out	20.70M
EPS (ttm)	1,795.21
PE Ratio	65.73
Forward PE	39.97
Dividend	500.00 (0.42%)
Ex-Dividend Date	Dec 27, 2024

Volume	241,403
Average Volume	188,648
Open	114,600
Previous Close	117,900
Day's Range	113,600 - 119,000
52-Week Range	66,600 - 121,600
Beta	0.25
RSI	70.36
Earnings Date	Feb 5, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2024, ST Pharm's revenue was 273.75 billion, a decrease of -3.94% compared to the previous year's 284.99 billion. Earnings were 34.71 billion, an increase of 77.27%.